Condition: Diabetes Mellitus, Type 2 · Sponsor: Novo Nordisk A/S
The study will look at how well insulin icodec controls blood sugar levels in participants who have never used it before. Participants with type 2 diabetes (T2D) will be treated with insulin icodec as prescribed to by their doctor, in accordance with usual clinical practice. This study will last for about 22 to 30 weeks.
This description comes directly from the study's public registry record.
Novo Nordisk · (+1) 866-867-7178 · clinicaltrials@novonordisk.com
Always discuss trial participation with your own doctor first.
| Azienda Sanitaria Locale Di Pescara | Pescara, Abruzzo, Italy | — |
| Azienda Ospedaliera-Universitaria Di Cosenza | San Giovanni in Fiore (CS), Calabria, Italy | — |
| Azienda Sanitaria Locale Napoli 2 Nord | Marano Di Napoli (NA), Campania, Italy | — |
| Azienda Ospedaliera Policlinico Universitario Tor Vergata | Rome, Lazio, Italy | — |
| Policlinico Casilino | Rome, Lazio, Italy | — |
| Azienda Ospedaliero - Universitaria Sant'Andrea - UOC Medicina interna | Rome, Lazio, Italy | — |
| Azienda Socio Sanitaria Territoriale Santi Paolo E Carlo | Milan, Lombardy, Italy | — |
| Grande Ospedale Metropolitano Niguarda - Dipartimento Medico Polispecialistico - Diabetologia | Milan, Lombardy, Italy | — |
| Azienda Ospedaliera Santa Croce E Carle | Cuneo, Piedmont, Italy | — |
| ARNAS Garibaldi Catania | Catania, Sicily, Italy | — |
| Ospedale centrale L. Bohler Bolzano | Bolzano, Trentino-Alto Adige, Italy | — |
| Azienda Ospedaliera di Padova | Padova, Veneto, Italy | — |
+ 3 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.